These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23453679)

  • 21. Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance.
    Lee LJ; Damato AL; Viswanathan AN
    Brachytherapy; 2013; 12(4):303-10. PubMed ID: 23491023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
    Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
    Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
    Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
    Adams Q; Hopfensperger KM; Kim Y; Wu X; Xu W; Shukla H; McGee J; Caster JM; Flynn RT
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1543-1550. PubMed ID: 30092333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes.
    Pohar S; Haq R; Liu L; Koniarczyk M; Hahn S; Damron T; Aronowitz JN
    Brachytherapy; 2007; 6(1):53-7. PubMed ID: 17284387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
    Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: a nonrandomized comparison of treatment results.
    Hsu WL; Wu CJ; Jen YM; Yen SH; Lin KT; Ger LP; Kim RY
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1425-31. PubMed ID: 7635783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.
    Murakami N; Kasamatsu T; Sumi M; Yoshimura R; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Ito Y; Itami J
    Radiat Oncol; 2014 Jan; 9():31. PubMed ID: 24456669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
    Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
    Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late chest wall toxicity after MammoSite breast brachytherapy.
    Brashears JH; Dragun AE; Jenrette JM
    Brachytherapy; 2009; 8(1):19-25. PubMed ID: 18955019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A surrogate urethra for real-time planning of high-dose-rate prostate brachytherapy.
    Halperin H; Hilts M; Crook J; Batchelar D; Tisseverasinghe S; Tetreault-LaFlamme A; Bachand F
    Brachytherapy; 2019; 18(5):675-682. PubMed ID: 31248822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results.
    Dimopoulos JC; Schmid MP; Fidarova E; Berger D; Kirisits C; Pötter R
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1880-8. PubMed ID: 21868174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.